Teva Pharmaceutical Industries (TEVA) Change in Cash (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Change in Cash came in at -$86.0 million in Q2 2026, down 118.53% YoY from $464.0 million in Q2 2025, and down 146.49% on a QoQ basis from $185.0 million in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Change in Cash (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Change in Cash data on file, last reported at -$86.0 million in Q2 2026.
- Quarterly Change in Cash fell 118.53% year-over-year to -$86.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.5 billion (up 1656.25% YoY) and the FY2025 annual result came in at $256.0 million, up 245.95% from the prior year.
- Change in Cash declined to -$86.0 million in Q2 2026, from $185.0 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $1.4 billion in Q4 2025 to a low of -$1.6 billion in Q1 2025.
- A 5-year average of $81.0 million and a median of $47.0 million in 2022 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2023 — Change in Cash sank 1365.38% — and 2025, when it surged 7616.67%.
- Tracing TEVA's Change in Cash over 5 years: stood at $576.0 million in 2022, then surged by 69.62% to $977.0 million in 2023, then plunged by 101.84% to -$18.0 million in 2024, then surged by 7616.67% to $1.4 billion in 2025, then slumped by 106.36% to -$86.0 million in 2026.
- The last three Change in Cash figures came in at -$86.0 million (Q2 2026), $185.0 million (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -86.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | -465.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -915.70 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 102.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 159.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -86.00 Mn |
| Mar 31, 2026 | 185.00 Mn |
| Dec 31, 2025 | 1.35 Bn |
| Sep 30, 2025 | 42.00 Mn |
| Jun 30, 2025 | 464.00 Mn |
| Mar 31, 2025 | -1.60 Bn |
| Dec 31, 2024 | -18.00 Mn |
| Sep 30, 2024 | 1.06 Bn |
| Jun 30, 2024 | -733.00 Mn |
| Mar 31, 2024 | -236.00 Mn |
| Dec 31, 2023 | 977.00 Mn |
| Sep 30, 2023 | -420.00 Mn |
| Jun 30, 2023 | 494.00 Mn |
| Mar 31, 2023 | -658.00 Mn |
| Dec 31, 2022 | 576.00 Mn |
| Sep 30, 2022 | 167.00 Mn |
| Jun 30, 2022 | -159.00 Mn |
| Mar 31, 2022 | 52.00 Mn |
| Dec 31, 2021 | 153.00 Mn |
| Sep 30, 2021 | -391.00 Mn |